Cyclerion Therapeutics, Inc.
CYCN
$3.43
$0.4213.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -83.64% | -91.17% | -95.20% | -97.05% | -95.89% |
| Gross Profit | 303.18% | 102.67% | 95.20% | 96.98% | 95.69% |
| SG&A Expenses | -35.88% | -39.59% | -36.84% | -44.63% | -41.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.65% | -50.28% | -46.80% | -69.26% | -73.51% |
| Operating Income | 62.39% | 51.85% | 46.80% | 68.89% | 72.74% |
| Income Before Tax | 75.72% | 65.30% | 23.72% | 56.74% | 64.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.72% | 65.30% | 23.72% | 56.74% | 64.12% |
| Earnings from Discontinued Operations | -- | -100.00% | 189.07% | 187.03% | 181.60% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.92% | 51.03% | 110.43% | 100.39% | 88.06% |
| EBIT | 62.39% | 51.85% | 46.80% | 68.89% | 72.74% |
| EBITDA | -- | 85.49% | 68.23% | 75.35% | 72.88% |
| EPS Basic | 53.32% | 59.37% | 109.59% | 99.76% | 87.09% |
| Normalized Basic EPS | 69.38% | 60.47% | 54.02% | 72.97% | 75.28% |
| EPS Diluted | 53.05% | 59.23% | 109.56% | 99.76% | 87.09% |
| Normalized Diluted EPS | 69.38% | 60.47% | 54.02% | 72.97% | 75.28% |
| Average Basic Shares Outstanding | 9.11% | 8.85% | 11.04% | 9.81% | 6.21% |
| Average Diluted Shares Outstanding | 9.11% | 8.85% | 11.04% | 9.81% | 6.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |